Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 42

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-4)

Sum=61

Publishing Process of This Article

Item

Count

Browse

Download

Sum=38

Nov 14, 2025 (publication date) through Nov 16, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Nov 14, 2025; 31(42): 111282
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.111282

Figure 1 Percentage of patients treated with tofacitinib 5 mg and 10 mg at week 52 with and without previous treatment with biologics.

Citation: Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; 31(42): 111282
URL: https://www.wjgnet.com/1007-9327/full/v31/i42/111282.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i42.111282

Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; 31(42): 111282 [DOI: 10.3748/wjg.v31.i42.111282]

©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA